Search Results 781-790 of 16387 for monoclonal antibody
A history of hypersensitivity to other humanized monoclonal antibodies. Significant cardiovascular disease (New York Heart Association Class II or greater) ...
Monoclonal antibodies;; Anti-HER2 or other "targeted" (e.g., mTOR) therapy. *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior ...
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find ...
CNS Autoantibody and Inflammatory Marker Investigation in Catatonia · Overview · Participation eligibility · Participating Mayo Clinic locations · More information ...
Participation eligibility · Chemotherapy < 21 days prior to first administration of study treatment and/or monoclonal antibody < 6 weeks prior to first ...
Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ...
Tetanus immune globulin works by giving your body the antibodies it needs to protect it against tetanus infection. This is called passive protection. This ...
Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. A history or presence of other medical illness that indicates ...
... antibodies and the factors that may determine disease progression and treatment response. ... Monoclonal antibodies, such as rituximab may block tumor growth in ...
Severe infection or inflammation at the time of Screening. 2. History of clinically significant hypersensitivity associated with monoclonal antibody
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your GivingTuesday gift can go 2X as far.